Stage IVB Lung Cancer AJCC v8 Recruiting Phase 2 Trials for Ceritinib (DB09063)

IndicationStatusPhase
DBCOND0111251 (Stage IVB Lung Cancer AJCC v8)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03737994Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)Treatment